Hereditary Angioedema Drug Market: Segmented: By Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Distribution Channel (Retail, Pharmacies, Hospital Pharmacies, Online Pharmacies), And Region - Global Analysis of Market Size, Share & Trends For 2019-2021 And Forecasts To 2031
[ 170 + Pages Research Report ] Hereditary Angioedema Drug Market to surpass USD 8.9 billion by 2031 from USD 2.9 billion in 2021 at a CAGR of 11.8% in the coming years, i.e., 2021-2031.
Uncommon autosomal dominant condition is known as C1-INH-HAE causes hereditary angioedema. In the past ten years, C1-INH-HAE management has benefited from the development of new medications and new uses for existing ones. The development of novel medications, some of which are now on the market for treating C1-INH-HAE, has been greatly aided by increased understanding of the pathophysiology of C1-INH-HAE, with suppression of the kallikrein-kinin system (plasma kallikrein, activated factor XII) as a primary area of focus. The three pillars of pharmacological therapy are short-term (pre-procedure) prevention, long-term prophylaxis, and treatment of acute angioedema attacks (on-demand medication).
Global Hereditary Angioedema Drug Market is expected to project a notable CAGR of 11.8% in 2031.
The market is anticipated to increase as a result of factors such as end-users rising need for technical improvements and rising investments in R&D, launches, collaborations, and other strategic initiatives. Additionally, authorities' increased emphasis on promoting urbanization and industrialization is anticipated to fuel market expansion.
The C1 Esterase Inhibitor segment is expected to grow with the highest CAGR during 2021-31
Based on Type, the global Hereditary Angioedema Drug Market is fragmented into C1 Esterase Inhibitors, Kallikrein Inhibitors, and Selective Bradykinin B2 Receptor Antagonists. In the market for treating hereditary angioedema, the C-1 esterase inhibitors category held a sizable market share. According to research and studies, 25% of cases of hereditary angioedema may result from spontaneous mutations of the C1-inhibitor gene in people who have no prior family history of the condition.
The Retail Pharmacies segment is expected to grow with the highest CAGR during 2021-31
Global Hereditary Angioedema Drug Market is classified on the basis of Distribution Channels into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. The category of retail pharmacies led the market for treating hereditary angioedema. Due to the increased use of online pharmacies, it is projected that the other segment will be more appealing.
Increasing Geriatric Population showcasing higher demand for Healthcare Services
A growing elderly population, which indicates a higher demand for healthcare services, is mostly to blame for the Hereditary Angioedema Drug Market's significant expansion. The majority of people with hereditary angioedema have their diagnoses for appendicitis, gastrointestinal issues, and other non-allergic angioedema errors. A sizable patient population with significant medical demands has been created as a result of a significant number of people having their ailment wrongly diagnosed. This is probably going to be a major market-increasing component.
Rising Initiatives for Improving Awareness Levels among Public
Another aspect fueling the market's expansion is the increase of activities aimed at raising public awareness. HAEday, which is observed annually on May 16th, is supported by HAE International (HAEi), an international patient group for people with hereditary angioedema as well as other patient organizations from across the world. The initiative's goals include expediting diagnosis and giving patients the best possible care and treatment.
High cost associated with the Hereditary Angioedema Drug
The market expansion is being severely hampered by the high cost of the medications used to treat hereditary angioedema. Cost control continues to be a barrier to the market's growth, despite efforts by pharmaceutical companies to develop newer, better medications for the acute attack and preventative treatment of hereditary angioedema.
Global Hereditary Angioedema Drug Market: Regions
Global Hereditary Angioedema Drug Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. Due to government measures to increase urbanization and population growth, which in turn leads to an increase in demand for energy-based goods and services, the Asia-Pacific market is predicted to develop quickly in the worldwide market. In addition, North America is expected to expand quickly due to the region's high energy consumption and industry-wide technology developments. The region's energy consumption has been rising, especially in the US; the main energy sources consumed include nuclear power, fossil fuels, coal, renewable energy, and natural gas.
The demand for and availability of non-COVID-19-related medical care has decreased as a result of the COVID-19 pandemic. Patients are delaying or avoiding a variety of treatments, including as urgent care for serious illnesses, regular checkups, and advised cancer screenings. Untreated illnesses and delayed treatment will have detrimental effects on long-term health. A number of current and emerging healthcare trends have been accelerated by COVID-19, including, among others, shifting consumer attitudes and behaviors, the integration of life science and healthcare, the rapid development of digital health technology, and new talent and care delivery models.
Global Hereditary Angioedema Drug Market is further segmented by region into:
Hereditary Angioedema Drug Market Segments:
|Market size value in 2021||USD 2.9 billion|
|Revenue forecast in 2031||USD 8.9 billion|
|Growth Rate||CAGR of 11.8% from 2021 to 2031|
|Base year for estimation||2020|
|Quantitative units||Revenue in USD million and CAGR from 2021 to 2031|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Segments covered||Type, Distribution Channel, and Region|
|Regional scope||North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)|
|Key companies profiled||Pharming Group NV, Takeda, CSL Limited, IBio Inc., BioCryst Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Attune Pharmaceuticals, Inc. and Other Prominent Players.|
Hereditary Angioedema Drug Market size was estimated at USD 2.9 billion in 2021 and is expected to reach USD 8.9 billion in 2031.
C1-esterase inhibitor deficiency (C1-INH-HAE) that causes hereditary angioedema, is an uncommon autosomal dominant disorder.
C1 Esterase Inhibitor segment accounted for the largest Hereditary Angioedema Drug Market share.
Key players in the Hereditary Angioedema Drug Market include Pharming Group NV, Takeda, CSL Limited, IBio Inc., BioCryst Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., and Other Prominent Players.
The Increasing Geriatric Population showcasing higher demand for Healthcare Services and Rising Initiatives for Improving Awareness Levels among Public.
Select License Type
US : +1 (716) 218-3733
UK : +44 (208) 1235555
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT